Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

Table 1 The characteristics of the myeloma patients included in the study

Patient	Age^d)	M-component	Transplant^a)	Conditioning therapy (drugs, number of cycles)		Effect of induction	CD34 count at the time of harvesting ^b)	Duration of cytopenia^c)
Patient	Age^d)	M-component	Transplant^a)	Pretransplant treatment	Number of cycles	Effect of induction	CD34 count at the time of harvesting ^b)	Neutrophils	Thrombocytes
1	60–70	IgG MM	Second	CVD	4	VGPR		5	2
2	60–70	IgG MM		CVD	4	VGPR	171,270	4	1
3	60–70	IgA MM	Second	CVD	4	VGPR		5	3
4	50–60	IgG MM		CVD	5	VGPR	32,180	5	5
5	50–60	IgG MM		CVD	5	PR	48,635	2	1
6	30–40	LCD		CVD (1), KRD (4)	5	VGPR	70,570	5	3
7	60–70	IgG MM		VTD (1), CVD (2)	3	VGPR	218,945	4	2
8	60–70	IgG MM		CVD	4	VGPR	90,930	4	4
9	60–70	IgA MM		CVD	5	PR	42,285	3	3
10	50–60	IgG MM	Second	PVD	6	PR		5	4
11	50–60	IgA MM		CVD	4	VGPR	32,125	5	4
12	60–70	IgA MM	Second	VRD	4	VGPR		5	2
13	60–70	LCD-L		CVD	4	VGPR	60,410	5	4
14	60–70	IgG MM		CVD, VTD, VD (3)	5	VGPR	123,190	6	1
15	60–70	IgG MM		VCD	4	PR	37,060	8	5
16	60–70	LCD-K		RD	4	VGPR	36,010	4	6
17	50–60	IgA-MM		CVD	4	VGPR	132,000	4	5
18	60–70	LCD-L		CVD (4 before and 2 after harvesting)	6	VGPR	27,690	5	5
19	50–60	IgG MM	Second	CVD	4	VGPR		5	3
20	50–60	Amyloid-MM IgG-L		CVD (3), VTD (1)	4		185,800	4	2
21	40–50	IgG MM		CVD (4 before harvesting), VTD (2 after), RD (2 after)	8	VGPR	56,380	4	6
22	50–60	LCD-L	Second	CVD	4	PR		7	5
23	50–60	IgG MM	Second	CVD, VTD, VD (4)	6	PR		5	5
24	50–60	LCD-L		CVD	4	VGPR	74,800	3	4
25	60–70	LCD-K	Second	CVD	4	PR		3	2

Abbreviations: CVD Cyclophosphamide, bortezomib (Velcade®), dexamethasone, LCD Light chain disease type lambda (L) or kappa (K), MM Multiple myeloma, PR Partial response, RD Lenalidomide (Revlemide®) plus dexamethasone, VGPR Very good partial response, VRD Bortezomib, lenalidomide (Revlemide®), dexamethasone, VTD Bortezomib (Velcade®), thalidomide, dexamethasone
^a) Patients undergoing their second auto-transplantation are indicated; the stem cell graft was the same as for the first transplantation for all these patients
^b) The peripheral blood concentration of CD34⁺ cells on the (first) day of harvesting is given; the level is expressed as × 10³ cells/mL
^c) Neutropenia was defined as the time from the first day of neutrophil peripheral blood concentration ≤ 0.2 × 10⁹/L until the first of three consecutive days with neutrophils exceeding 0.2 × 10⁹/L or alternatively the first day with neutrophil counts > 10 × 10⁹/L. The duration of thrombocytopenia was defined as the number of days from the first day of peripheral blood thrombocyte counts below 20 × 10⁹/L until the first day with thrombocyte count above 20 × 10⁹/L without thrombocyte transfusion
^d) The age of patients are grouped

ISSN: 1471-2172